Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 64 | BES2019 | Next issue

Belgian Endocrine Society 2019

BES 2019

Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study

ea0064007 | Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study | BES2019

Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study

Constantinescu SM , Lefebvre A , Furnica RM , Maiter D

Introduction: Severe Cushing’s syndrome (CS) is defined by extremely high serum cortisol levels (usually >1000 nM), along with severe and deadly complications, including sepsis, heart failure, acute psychosis, vascular thrombosis, digestive haemorrhage and bowel perforation. Rapid control of such hypercortisolism is mandatory and has been shown to decrease operative mortality and complications. Oral treatments such as ketoconazole and metyrapone are often inadequate i...